Download Files:
Products Details
Product Description
– PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.
Web ID
– HY-13461
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C12H11N3O
Citations
– Acta Pharmacol Sin. 2021 Jun 29.|Autophagy. 2021 Dec 10;1-19.|Sci Rep. 2021 Mar 8;11(1):5374.
References
– [1]Montagnoli A, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4(6):357-65.|[2]Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9(11):e113300.|[3]Li W, et al. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15(3):196-204.|[4]Erbayraktar Z, et al. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 2016 Nov 18;16:88.
CAS Number
– 845714-00-3
Molecular Weight
– 213.24
SMILES
– O=C1C2=C(NC(C3=CC=NC=C3)=C2)CCN1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– CDK
Isoform
– CDK1;CDK2;CDK5;CDK9
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
